Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 37

1.

Acute Myeloid Leukemia, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology.

Tallman MS, Wang ES, Altman JK, Appelbaum FR, Bhatt VR, Bixby D, Coutre SE, De Lima M, Fathi AT, Fiorella M, Foran JM, Hall AC, Jacoby M, Lancet J, LeBlanc TW, Mannis G, Marcucci G, Martin MG, Mims A, O'Donnell MR, Olin R, Peker D, Perl A, Pollyea DA, Pratz K, Prebet T, Ravandi F, Shami PJ, Stone RM, Strickland SA, Wieduwilt M, Gregory KM; OCN, Hammond L, Ogba N.

J Natl Compr Canc Netw. 2019 Jun 1;17(6):721-749. doi: 10.6004/jnccn.2019.0028.

PMID:
31200351
2.

Venetoclax Combined With Low-Dose Cytarabine for Previously Untreated Patients With Acute Myeloid Leukemia: Results From a Phase Ib/II Study.

Wei AH, Strickland SA Jr, Hou JZ, Fiedler W, Lin TL, Walter RB, Enjeti A, Tiong IS, Savona M, Lee S, Chyla B, Popovic R, Salem AH, Agarwal S, Xu T, Fakouhi KM, Humerickhouse R, Hong WJ, Hayslip J, Roboz GJ.

J Clin Oncol. 2019 May 20;37(15):1277-1284. doi: 10.1200/JCO.18.01600. Epub 2019 Mar 20.

PMID:
30892988
3.

A Novel MCL1 Inhibitor Combined with Venetoclax Rescues Venetoclax-Resistant Acute Myelogenous Leukemia.

Ramsey HE, Fischer MA, Lee T, Gorska AE, Arrate MP, Fuller L, Boyd KL, Strickland SA, Sensintaffar J, Hogdal LJ, Ayers GD, Olejniczak ET, Fesik SW, Savona MR.

Cancer Discov. 2018 Dec;8(12):1566-1581. doi: 10.1158/2159-8290.CD-18-0140. Epub 2018 Sep 5.

4.

Final results of a randomized multicenter phase II study of alvocidib, cytarabine, and mitoxantrone versus cytarabine and daunorubicin (7 + 3) in newly diagnosed high-risk acute myeloid leukemia (AML).

Zeidner JF, Foster MC, Blackford AL, Litzow MR, Morris LE, Strickland SA, Lancet JE, Bose P, Levy MY, Tibes R, Gojo I, Gocke CD, Rosner GL, Little RF, Wright JJ, Doyle LA, Smith BD, Karp JE.

Leuk Res. 2018 Sep;72:92-95. doi: 10.1016/j.leukres.2018.08.005. Epub 2018 Aug 10. No abstract available.

PMID:
30118897
5.

Dietary exposure to a binary mixture of polybrominated diphenyl ethers alters innate immunity and disease susceptibility in juvenile Chinook salmon (Oncorhynchus tshawytscha).

Arkoosh MR, Van Gaest AL, Strickland SA, Hutchinson GP, Krupkin AB, Hicks MBR, Dietrich JP.

Ecotoxicol Environ Saf. 2018 Nov 15;163:96-103. doi: 10.1016/j.ecoenv.2018.07.052. Epub 2018 Jul 21.

PMID:
30041130
6.

CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia.

Lancet JE, Uy GL, Cortes JE, Newell LF, Lin TL, Ritchie EK, Stuart RK, Strickland SA, Hogge D, Solomon SR, Stone RM, Bixby DL, Kolitz JE, Schiller GJ, Wieduwilt MJ, Ryan DH, Hoering A, Banerjee K, Chiarella M, Louie AC, Medeiros BC.

J Clin Oncol. 2018 Sep 10;36(26):2684-2692. doi: 10.1200/JCO.2017.77.6112. Epub 2018 Jul 19.

7.

Phase 3 results for vosaroxin/cytarabine in the subset of patients ≥60 years old with refractory/early relapsed acute myeloid leukemia.

Ravandi F, Ritchie EK, Sayar H, Lancet JE, Craig MD, Vey N, Strickland SA, Schiller GJ, Jabbour E, Pigneux A, Horst HA, Récher C, Klimek VM, Cortes JE, Carella AM, Egyed M, Krug U, Fox JA, Craig AR, Ward R, Smith JA, Acton G, Kantarjian HM, Stuart RK.

Haematologica. 2018 Nov;103(11):e514-e518. doi: 10.3324/haematol.2018.191361. Epub 2018 May 24. No abstract available.

8.

Genotypic and clinical heterogeneity within NCCN favorable-risk acute myeloid leukemia.

Strickland SA, Shaver AC, Byrne M, Daber RD, Ferrell PB, Head DR, Mohan SR, Mosse CA, Moyo TK, Stricker TP, Vnencak-Jones C, Savona MR, Seegmiller AC.

Leuk Res. 2018 Feb;65:67-73. doi: 10.1016/j.leukres.2017.12.012. Epub 2018 Jan 2.

9.

Acute Myeloid Leukemia, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology.

O'Donnell MR, Tallman MS, Abboud CN, Altman JK, Appelbaum FR, Arber DA, Bhatt V, Bixby D, Blum W, Coutre SE, De Lima M, Fathi AT, Fiorella M, Foran JM, Gore SD, Hall AC, Kropf P, Lancet J, Maness LJ, Marcucci G, Martin MG, Moore JO, Olin R, Peker D, Pollyea DA, Pratz K, Ravandi F, Shami PJ, Stone RM, Strickland SA, Wang ES, Wieduwilt M, Gregory K, Ogba N.

J Natl Compr Canc Netw. 2017 Jul;15(7):926-957. doi: 10.6004/jnccn.2017.0116.

PMID:
28687581
10.

Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1-2 study.

Perl AE, Altman JK, Cortes J, Smith C, Litzow M, Baer MR, Claxton D, Erba HP, Gill S, Goldberg S, Jurcic JG, Larson RA, Liu C, Ritchie E, Schiller G, Spira AI, Strickland SA, Tibes R, Ustun C, Wang ES, Stuart R, Röllig C, Neubauer A, Martinelli G, Bahceci E, Levis M.

Lancet Oncol. 2017 Aug;18(8):1061-1075. doi: 10.1016/S1470-2045(17)30416-3. Epub 2017 Jun 20. Erratum in: Lancet Oncol. 2017 Dec;18(12 ):e711. Lancet Oncol. 2018 Jul;19(7):e335. Erratum in: Lancet Oncol. 2019 Jun;20(6):e293.

11.

Independent Prognostic Significance of Monosomy 17 and Impact of Karyotype Complexity in Monosomal Karyotype/Complex Karyotype Acute Myeloid Leukemia: Results from Four ECOG-ACRIN Prospective Therapeutic Trials.

Strickland SA, Sun Z, Ketterling RP, Cherry AM, Cripe LD, Dewald G, Fernandez HF, Hicks GA, Higgins RR, Lazarus HM, Litzow MR, Luger SM, Paietta EM, Rowe JM, Vance GH, Wiernik P, Wiktor AE, Zhang Y, Tallman MS; ECOG-ACRIN Cancer Research Group.

Leuk Res. 2017 Aug;59:55-64. doi: 10.1016/j.leukres.2017.05.010. Epub 2017 May 12.

12.

MicroRNAs and tRNA-derived fragments predict the transformation of myelodysplastic syndromes to acute myeloid leukemia.

Guo Y, Strickland SA, Mohan S, Li S, Bosompem A, Vickers KC, Zhao S, Sheng Q, Kim AS.

Leuk Lymphoma. 2017 Sep;58(9):1-15. doi: 10.1080/10428194.2016.1272680. Epub 2017 Jan 13.

13.

Alteration of thyroid hormone concentrations in juvenile Chinook salmon (Oncorhynchus tshawytscha) exposed to polybrominated diphenyl ethers, BDE-47 and BDE-99.

Arkoosh MR, Van Gaest AL, Strickland SA, Hutchinson GP, Krupkin AB, Dietrich JP.

Chemosphere. 2017 Mar;171:1-8. doi: 10.1016/j.chemosphere.2016.12.035. Epub 2016 Dec 8.

PMID:
28006665
14.

High-Resolution Mapping of RNA Polymerases Identifies Mechanisms of Sensitivity and Resistance to BET Inhibitors in t(8;21) AML.

Zhao Y, Liu Q, Acharya P, Stengel KR, Sheng Q, Zhou X, Kwak H, Fischer MA, Bradner JE, Strickland SA, Mohan SR, Savona MR, Venters BJ, Zhou MM, Lis JT, Hiebert SW.

Cell Rep. 2016 Aug 16;16(7):2003-16. doi: 10.1016/j.celrep.2016.07.032. Epub 2016 Aug 4.

15.

Molecular and Pharmacologic Properties of the Anticancer Quinolone Derivative Vosaroxin: A New Therapeutic Agent for Acute Myeloid Leukemia.

Jamieson GC, Fox JA, Poi M, Strickland SA.

Drugs. 2016 Sep;76(13):1245-1255. doi: 10.1007/s40265-016-0614-z. Review.

16.

Unfavorable-risk acute myeloid leukemia dissected.

Strickland SA, Mohan SR, Savona MR.

Curr Opin Hematol. 2016 Mar;23(2):144-9. doi: 10.1097/MOH.0000000000000225. Review.

PMID:
26825699
17.

Transfer RNA detection by small RNA deep sequencing and disease association with myelodysplastic syndromes.

Guo Y, Bosompem A, Mohan S, Erdogan B, Ye F, Vickers KC, Sheng Q, Zhao S, Li CI, Su PF, Jagasia M, Strickland SA, Griffiths EA, Kim AS.

BMC Genomics. 2015 Sep 24;16:727. doi: 10.1186/s12864-015-1929-y.

18.

Vosaroxin plus cytarabine versus placebo plus cytarabine in patients with first relapsed or refractory acute myeloid leukaemia (VALOR): a randomised, controlled, double-blind, multinational, phase 3 study.

Ravandi F, Ritchie EK, Sayar H, Lancet JE, Craig MD, Vey N, Strickland SA, Schiller GJ, Jabbour E, Erba HP, Pigneux A, Horst HA, Recher C, Klimek VM, Cortes J, Roboz GJ, Odenike O, Thomas X, Havelange V, Maertens J, Derigs HG, Heuser M, Damon L, Powell BL, Gaidano G, Carella AM, Wei A, Hogge D, Craig AR, Fox JA, Ward R, Smith JA, Acton G, Mehta C, Stuart RK, Kantarjian HM.

Lancet Oncol. 2015 Sep;16(9):1025-1036. doi: 10.1016/S1470-2045(15)00201-6. Epub 2015 Jul 30.

19.

Randomized multicenter phase II study of flavopiridol (alvocidib), cytarabine, and mitoxantrone (FLAM) versus cytarabine/daunorubicin (7+3) in newly diagnosed acute myeloid leukemia.

Zeidner JF, Foster MC, Blackford AL, Litzow MR, Morris LE, Strickland SA, Lancet JE, Bose P, Levy MY, Tibes R, Gojo I, Gocke CD, Rosner GL, Little RF, Wright JJ, Doyle LA, Smith BD, Karp JE.

Haematologica. 2015 Sep;100(9):1172-9. doi: 10.3324/haematol.2015.125849. Epub 2015 May 28.

20.

Dietary Exposure to Individual Polybrominated Diphenyl Ether Congeners BDE-47 and BDE-99 Alters Innate Immunity and Disease Susceptibility in Juvenile Chinook Salmon.

Arkoosh MR, Van Gaest AL, Strickland SA, Hutchinson GP, Krupkin AB, Dietrich JP.

Environ Sci Technol. 2015 Jun 2;49(11):6974-81. doi: 10.1021/acs.est.5b01076. Epub 2015 May 15.

PMID:
25938634
21.

Assimilation efficiency of PBDE congeners in Chinook salmon.

Dietrich JP, Strickland SA, Hutchinson GP, Van Gaest AL, Krupkin AB, Ylitalo GM, Arkoosh MR.

Environ Sci Technol. 2015 Mar 17;49(6):3878-86. doi: 10.1021/es5057038. Epub 2015 Feb 27.

PMID:
25692390
22.

REVEAL-1, a phase 2 dose regimen optimization study of vosaroxin in older poor-risk patients with previously untreated acute myeloid leukaemia.

Stuart RK, Cripe LD, Maris MB, Cooper MA, Stone RM, Dakhil SR, Turturro F, Stock W, Mason J, Shami PJ, Strickland SA, Costa LJ, Borthakur G, Michelson GC, Fox JA, Leavitt RD, Ravandi F.

Br J Haematol. 2015 Mar;168(6):796-805. doi: 10.1111/bjh.13214. Epub 2014 Nov 17.

23.

Toxicity of PHOS-CHEK LC-95A and 259F fire retardants to ocean- and stream-type Chinook salmon and their potential to recover before seawater entry.

Dietrich JP, Van Gaest AL, Strickland SA, Hutchinson GP, Krupkin AB, Arkoosh MR.

Sci Total Environ. 2014 Aug 15;490:610-21. doi: 10.1016/j.scitotenv.2014.05.038. Epub 2014 Jun 2.

PMID:
24880550
24.

The impact of temperature stress and pesticide exposure on mortality and disease susceptibility of endangered Pacific salmon.

Dietrich JP, Van Gaest AL, Strickland SA, Arkoosh MR.

Chemosphere. 2014 Aug;108:353-9. doi: 10.1016/j.chemosphere.2014.01.079. Epub 2014 Feb 20.

PMID:
24559935
25.

Expression of putative targets of immunotherapy in acute myeloid leukemia and healthy tissues.

Goswami M, Hensel N, Smith BD, Prince GT, Qin L, Levitsky HI, Strickland SA, Jagasia M, Savani BN, Fraser JW, Sadrzadeh H, Rajkhowa T, Ito S, Jain NA, Battiwalla M, Fathi AT, Levis MJ, Barrett AJ, Hourigan CS.

Leukemia. 2014 May;28(5):1167-70. doi: 10.1038/leu.2014.14. Epub 2014 Jan 10. No abstract available.

26.

Optimizing personalized bone marrow testing using an evidence-based, interdisciplinary team approach.

Seegmiller AC, Kim AS, Mosse CA, Levy MA, Thompson MA, Kressin MK, Jagasia MH, Strickland SA, Reddy NM, Marx ER, Sinkfield KJ, Pollard HN, Plummer WD, Dupont WD, Shultz EK, Dittus RS, Stead WW, Santoro SA, Zutter MM.

Am J Clin Pathol. 2013 Nov;140(5):643-50. doi: 10.1309/AJCP8CKE9NEINQFL.

27.

Acute myeloid leukemia, version 2.2013.

O'Donnell MR, Tallman MS, Abboud CN, Altman JK, Appelbaum FR, Arber DA, Attar E, Borate U, Coutre SE, Damon LE, Lancet J, Maness LJ, Marcucci G, Martin MG, Millenson MM, Moore JO, Ravandi F, Shami PJ, Smith BD, Stone RM, Strickland SA, Wang ES, Gregory KM, Naganuma M; National Comprehensive Cancer Network.

J Natl Compr Canc Netw. 2013 Sep 1;11(9):1047-55.

28.

Toxicity of forest fire retardant chemicals to stream-type chinook salmon undergoing parr-smolt transformation.

Dietrich JP, Myers MS, Strickland SA, Van Gaest A, Arkoosh MR.

Environ Toxicol Chem. 2013 Jan;32(1):236-47. doi: 10.1002/etc.2052. Epub 2012 Nov 26.

PMID:
23161484
29.

Oral sapacitabine for the treatment of acute myeloid leukaemia in elderly patients: a randomised phase 2 study.

Kantarjian H, Faderl S, Garcia-Manero G, Luger S, Venugopal P, Maness L, Wetzler M, Coutre S, Stock W, Claxton D, Goldberg SL, Arellano M, Strickland SA, Seiter K, Schiller G, Jabbour E, Chiao J, Plunkett W.

Lancet Oncol. 2012 Nov;13(11):1096-104. doi: 10.1016/S1470-2045(12)70436-9. Epub 2012 Oct 15.

30.

Correlation of the microculture-kinetic drug-induced apoptosis assay with patient outcomes in initial treatment of adult acute myelocytic leukemia.

Strickland SA, Raptis A, Hallquist A, Rutledge J, Chernick M, Perree M, Talbott MS, Presant CA.

Leuk Lymphoma. 2013 Mar;54(3):528-34. doi: 10.3109/10428194.2012.722217. Epub 2012 Sep 17.

PMID:
22924433
31.

NCCN Clinical Practice Guidelines Acute myeloid leukemia.

O'Donnell MR, Abboud CN, Altman J, Appelbaum FR, Arber DA, Attar E, Borate U, Coutre SE, Damon LE, Goorha S, Lancet J, Maness LJ, Marcucci G, Millenson MM, Moore JO, Ravandi F, Shami PJ, Smith BD, Stone RM, Strickland SA, Tallman MS, Wang ES, Naganuma M, Gregory KM.

J Natl Compr Canc Netw. 2012 Aug;10(8):984-1021.

PMID:
22878824
32.

Allo-SCT for high-risk AML-CR1 in the molecular era: impact of FLT3/ITD outweighs the conventional markers.

Sengsayadeth SM, Jagasia M, Engelhardt BG, Kassim A, Strickland SA, Goodman S, Lucid C, Vnencak-Jones CL, Greer JP, Savani BN.

Bone Marrow Transplant. 2012 Dec;47(12):1535-7. doi: 10.1038/bmt.2012.88. Epub 2012 Jun 4.

PMID:
22659680
33.

Survey of pathogens in hatchery Chinook salmon with different out-migration histories through the Snake and Columbia rivers.

Van Gaest AL, Dietrich JP, Thompson DE, Boylen DA, Strickland SA, Collier TK, Loge FJ, Arkoosh MR.

J Aquat Anim Health. 2011 Jun;23(2):62-77.

PMID:
21834329
34.

Acute myeloid leukemia.

O'Donnell MR, Abboud CN, Altman J, Appelbaum FR, Coutre SE, Damon LE, Foran JM, Goorha S, Maness LJ, Marcucci G, Maslak P, Millenson MM, Moore JO, Ravandi F, Shami PJ, Smith BD, Stone RM, Strickland SA, Tallman MS, Wang ES; National Comprehensive Cancer Network.

J Natl Compr Canc Netw. 2011 Mar;9(3):280-317. No abstract available.

PMID:
21393440
35.

Extramedullary relapses after allogeneic stem cell transplantation for acute myeloid leukemia and myelodysplastic syndrome.

Clark WB, Strickland SA, Barrett AJ, Savani BN.

Haematologica. 2010 Jun;95(6):860-3. doi: 10.3324/haematol.2010.025890. Review. No abstract available.

36.

Hiccups: underappreciated and underrecognized.

Strickland SA Jr, Berlin JD.

J Support Oncol. 2009 Jul-Aug;7(4):128-9. No abstract available.

PMID:
19731576
37.

Double cheek-cervical rotation flap for repair of facial defects.

Lim RY, Strickland SA, Lim JW.

W V Med J. 1993 Jan;89(1):18-20.

PMID:
8421911

Supplemental Content

Loading ...
Support Center